Cundell Anthony M
Consulting Microbiologist, Scarsdale, New York, USA
PDA J Pharm Sci Technol. 2014 Jul-Aug;68(4):323-32. doi: 10.5731/pdajpst.2014.00988.
This review article will provide general guidance to product development scientists for the justification for the use of aseptic filling for sterile injectable products in the place of terminal sterilization using moist heat. The discussion is centered on the position of U.S. and European regulatory agencies on aseptic processing versus terminal sterilization, and regulatory actions-that is, 483 observations, warning letters, and product recalls-associated with a lack of sterility assurance of aseptically filled injectable products. Also discussed are the sterility assurance levels achieved using terminal sterilization and aseptic processing, sterilization processes used for terminal sterilization, compatibility of different product, product packaging and delivery systems with terminal sterilization, physicochemical stability of product during a terminal sterilization process, and storage during the product shelf life. The author believes that a better understanding of the options surrounding terminal sterilization will result in fewer products being aseptically filled.
这篇综述文章将为产品开发科学家提供一般指导,以说明在无菌注射产品中使用无菌灌装代替湿热终端灭菌的理由。讨论集中在美国和欧洲监管机构对无菌工艺与终端灭菌的立场,以及与无菌灌装注射产品无菌保证不足相关的监管行动,即483表观察结果、警告信和产品召回。还讨论了使用终端灭菌和无菌工艺实现的无菌保证水平、用于终端灭菌的灭菌工艺、不同产品、产品包装和递送系统与终端灭菌的兼容性、产品在终端灭菌过程中的物理化学稳定性以及产品保质期内的储存。作者认为,更好地理解围绕终端灭菌的选择将导致进行无菌灌装的产品减少。